Seagen has a new suitor as Pfizer talks begin— After spending $6.5B for Momenta, J&J readies 'pipeline in a product' for pivotal year—Ahead of FDA decision, Blueprint puts out full data for expanded Ayvakit label-- See more on our front page news http://bit.ly/w28kSd #seagen #pfizer #mergersandacquisitions #jnj #janssen #fda #blueprintmedicines #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#seagen #pfizer #mergersandacquisitions #jnj #Janssen #FdA #blueprintmedicines #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma